Alydia Health is focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding – a challenging condition to manage and a growing problem in the United States and globally.

Alydia’s device, the Jada System, is designed to encourage normal contraction of the uterus to stop excessive bleeding after childbirth. Alydia received FDA 510(k) clearance for the Jada System in August 2020 based on results from the company’s pivotal PEARLE study.

Alydia recently announced an agreement with Merck pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health.